Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE NEW PRODUCTS
July 23, 2007
-
ARCHIVE Profits Should Be Transferred from Long-Listed Drugs to New Drugs: Mr Yamabe
July 23, 2007
-
ARCHIVE Nippon Kayaku Aims at Sales of \10 Billion with Generics
July 16, 2007
-
ARCHIVE Takeda's MRs to Deal with All of Its Products: Mr Yamanaka
July 16, 2007
-
ARCHIVE Nippon Shinyaku to Rebuild Pipeline with Niche Products: New President Maekawa
July 16, 2007
-
ARCHIVE Adhesives Most Preferred Dosage Form of Narcotics for Cancer Pain
July 16, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 16, 2007
-
ARCHIVE Research to Prevent Progression of CKD to Dialysis to Start
July 16, 2007
-
ARCHIVE Expenditures under NHI Programs in 2006 Rose Only 0.5%
July 16, 2007
-
ARCHIVE R&D NEWS IN BRIEF
July 16, 2007
-
ARCHIVE Draft Guidance for MD Studies Presented
July 16, 2007
-
ARCHIVE 420 Generics Receive NHI Price Listing
July 16, 2007
-
ARCHIVE Astellas, Kyoto Univ. Start Collaborative Drug Discovery
July 16, 2007
-
ARCHIVE 10 APIs Recommended for Approval by CDFS's Dept. on Drugs
July 16, 2007
-
ARCHIVE AntiCancer Inc. Opens Bioimaging Research Lab in Osaka
July 16, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
July 16, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 16, 2007
-
ARCHIVE Banyu's Preminent Shows Highest Awareness Rate: Survey
July 16, 2007
-
ARCHIVE Ryukaikon to Focus on Business Between Makers and Wholesalers
July 16, 2007
-
ARCHIVE Eyeforpharma Sales Force Effectiveness Japan 2007
July 16, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…